Our assessment
Bottom line
Suki is an established commercial documentation product, but the represented evidence base is weighted toward company and customer reports. Publicly available information supports its workflow use more clearly than its comparative clinical accuracy or long-term safety.
Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.
What the evidence supports
Reviewed official materials establish a marketed ambient and voice documentation assistant.
What remains uncertain
Independent evidence on clinical error rates, subgroup performance, and downstream record quality remains limited in this profile.
How it was studied
Public Suki materials emphasize deployment, integration, clinician adoption, and time saved. This initial Atlas review has not yet identified a public pivotal trial that independently measures severe factual errors or patient-level outcomes for the current product version.